Skip to main content
profile image
Selected Works of Steven Borzak, MD, FACC
Article
Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study.
Circulation (2001)
  • Kenneth W. Baran, John Nasseff Heart Hospital
  • Michel Nguyen, UniversitĂ© de Sherbrooke
  • George R. McKendall, Rhode Island Hospital
  • Costas T. Lambrew, Maine Medical Center
  • Gary Dykstra, Philips
  • Sebastian T. Palmeri, Rutgers University
  • Raymond J. Gibbons, Cardiovascular Medicine
  • Steven Borzak, Henry Ford Health System
  • Burton E. Sobel, University of Vermont
  • Steven G. Gourlay, University of California, San Francisco
  • Steven G. Gourlay, Genentech
  • Amy Chen Rundle, Genentech
  • C. Michael Gibson, University of California, San Francisco
  • Hal V. Barron, University of California, San Francisco
  • Hal V. Barron, Genentech
Link
Disciplines
Publication Date
December 4, 2001
DOI
10.1161/HC4801.100236
Citation Information
Kenneth W. Baran, Michel Nguyen, George R. McKendall, Costas T. Lambrew, et al.. "Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study." Circulation Vol. 104 Iss. 23 (2001) p. 2778 - 2783
Available at: http://works.bepress.com/steven-borzak/80/